Source: American journal of kidney diseases. Unidade: FM
Subjects: ANEMIA, ERITROPOIETINA, HEMODIÁLISE, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAUSLAND, Finnian R. Mc et al. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). American journal of kidney diseases, v. 73, n. 3, p. 309-315, 2019Tradução . . Disponível em: https://doi.org/10.1053/j.ajkd.2018.10.006. Acesso em: 17 out. 2024.APA
Causland, F. R. M., Claggett, B., Burdmann, E. de A., Chertow, G. M., Cooper, M. E., Eckardt, K. -U., et al. (2019). Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). American journal of kidney diseases, 73( 3), 309-315. doi:10.1053/j.ajkd.2018.10.006NLM
Causland FRM, Claggett B, Burdmann E de A, Chertow GM, Cooper ME, Eckardt K-U, Ivanovich P, Levey AS, Lewis EF, Mcgill JB. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) [Internet]. American journal of kidney diseases. 2019 ; 73( 3): 309-315.[citado 2024 out. 17 ] Available from: https://doi.org/10.1053/j.ajkd.2018.10.006Vancouver
Causland FRM, Claggett B, Burdmann E de A, Chertow GM, Cooper ME, Eckardt K-U, Ivanovich P, Levey AS, Lewis EF, Mcgill JB. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) [Internet]. American journal of kidney diseases. 2019 ; 73( 3): 309-315.[citado 2024 out. 17 ] Available from: https://doi.org/10.1053/j.ajkd.2018.10.006
